Welcome to the March 2015 issue of FREYRFOREWORD!

A monthly round-up of the latest happenings and updates from Freyr.
Happy Reading!

Cosmetic products have an estimated worth of €67bn in Europe, which is regarded as a massive enterprise. The primary requirement during the development of a cosmetic product is to ensure protection for the user’s health which is also the basis of the cosmetic legislation. This protection also enables increased consumer confidence in the brand.


Cosmetics regulation is the main regulatory framework for finished cosmetic products in the EU market. The main aim of the regulation is to ensure protection of consumer’s health and making consumer’s well informed by monitoring the composition and labeling of products and assessment of product safety and mainly focusing on the prohibition of animal testing.The first law governing the manufacture and marketing of safe cosmetic products was introduced in the European Union (EU) in 1976 in the form of a Directive (76/768/EEC). The Cosmetics Regulation, adopted in 2009, replaces Directive 76/768/EC that was adopted in 1976 and had been substantially revised on numerous occasions.Since 11 July 2013, the new EU Regulation 1223/2009 (Cosmetics Regulation) is in force.

  • It strengthens the safety of cosmetic products and streamlines the framework for all operators in the sector
  • The regulation simplifies procedures to the extent that the internal market of cosmetic products is now a reality



Manufacturers must follow specific requirements for preparation of a product safety report ahead of placing a product on the market. As per Scientific Committee on Consumer Safety (SCCS) guidelines, a cosmetic product made available on the market shall be safe for human health when used under normal or reasonably foreseeable conditions of use, taking in account like instructions for use and disposal, labeling and any other indication or information provided by the responsible person.


Assessment of safety, which is also deemed as full safety assessment, is to be conducted by a responsible person on the basis of the relevant information. A cosmetic product safety report (CPSR) needs to be generated for every cosmetic product prior to placing the products in the market.

In accordance to SCCS guidelines, data on Serious Undesirable Effects (SUE) as well as on any undesirable effect become part of the CPSR.

There are two sections in a CPSR, the first section covers “cosmetics safety information” while the second section covers “cosmetics safety assessment”. In addition, No Observed Adverse Effect Level (NOAEL) is the starting point used to calculate the margin of safety (MoS). It is compulsory to state the reasons, if there is no relevant assessment performed. Furthermore, the microbiological quality report and stability test report must also be submitted before safety assessors embark on the final signing of cosmetics safety reports.


A responsible person will be in charge of notifying Serious Undesirable Effects (SUE) to competent national authorities who will also collect information from users and health professionals.The information will be readily available to share within other EU Member States.


Colorants, preservatives UV-filters and nanomaterials must be explicitly authorized and other nanomaterials present in a product which are not restricted by the Cosmetics Regulation will be the object of a full safety assessment at the EU level. Nanomaterials must be labeled in the ingredients list with the word ‘nano’ in brackets following the name of the substance, e.g. “titanium dioxide (nano)”.



As per SCCS guidelines, prior to placing the cosmetic product on the market the responsible person shall submit, the following information to the Commission by electronic means

  • Category of cosmetic product and its name
  • Name and address of the responsible person
  • Country of origin
  • Member State in which the cosmetic product is to be placed on the market
  • Contact details of a physical person
  •  The presence of substances in the form of nanomaterial
  • The name and the Chemicals Abstracts Service (CAS) or EC number of substances classified as carcinogenic, mutagenic or toxic for reproduction(CMR)


It is a centralized notification procedure opted throughout EU for all cosmetic products placed on the EU market. Before placing a product in the market, every manufacturer has to ensure that the product is notified in EU Cosmetic Products Notification Portal (CPNP). It is a free of charge online notification system; CPNP has been created for the implementation of Regulation (EC) No 1223/2009 on cosmetic products.

As it is a one-time procedure there is no need for any further notification at the national level in the EU. All information is available electronically to Competent Authorities and Poison Centre’s or similar bodies.


For every cosmetic product (placed on market) there is a Product Information file created and maintained by the responsible person for a period of ten years (following the date on which the last batch of the cosmetic product was placed on the market).


It is mandatory to have listed all ingredients in the cosmetic container labels using identical terms based on the International Nomenclature for Cosmetics Ingredients (INCI) across the whole European Union. Label should include:

  • Name and address of the manufacturer, importer or distributor
  • Nominal content by weight or volume
  • Date of minimum durability or Period After Opening (PAO) for products lasting more than 30 months
  • Precautions to be observed in use
  • Goods identification reference (e.g. a batch number/manufacturing code)
  • Function of the product (unless it is clear from the presentation)


Member States shall not, refuse, prohibit or restrict cosmetic products availablility on the market which comply with the requirements of regulation.


As per new regulation and guidelines, it is stated as not to have any testing of finished cosmetic products and cosmetic ingredients on animals in the European Union.



Counterfeiting, theft, diversion and false returns to manufacturers are few of the problems faced by the pharmaceutical industry across the globe. According to the World Health Organization (WHO), counterfeit drugs make up 1% of the supply in developed countries (including millions of prescriptions in the US alone) and 30-40% in developing countries. By implementing product serialization, counterfeiting by organized crime can be considerably reduced according to pharmaceutical companies and governments of countries across the globe.



It refers to the allocation and placement of unique markings on a primary package. The markings can be a two-dimensional or RSS bar code, a human readable letter/number code or unique serialized codes that can be written onto a radio-frequency identification (RFID) tag/label. Variable data printers or preprinted labels or cartons are employed to position unique codes on each package which are then read by a vision system. Furthermore, the unique codes are uploaded to an event repository database which can be accessed by various parties, including pharmacists, law enforcement officials and even consumers, once the product is shipped and sold.

The individual packages will have unique codes which can be grouped/electronically linked to a shipping case and even to a pallet and other levels of packaging which in turn creates a child/parent/ grandparent relationship. As a result of the grouping, if the bar code on a pallet is scanned at a warehouse, the brand owner or trading partner will have tracking information regarding all shipping containers and primary containers at that warehouse. In addition, once an ePedigree law comes into action, serialization and aggregation will help to track-and-trace products from the point of packaging to the pharmacy or healthcare facility.



Serialization requirements are in heterogeneous stages of development in the US, Canada, EU and in its member nations as well as in Turkey, India, China, Brazil, Argentina and South Korea. Despite the variations found in countries laws, each nation’s regulations tend to be built around GS1 standards and are quite similar. Although the GS1 format is the most desirable standard, International Organization for Standardization (ISO), Internet Engineering Task Force (IETF) and other competing standards also apply to serialization. All activities related to drug serialization that are evolving in different countries are backed up by the overarching global initiative conducted on the World Health Organization (WHO) level. The WHO set up the International Medical Products Anti- Counterfeiting Taskforce (IMPACT).

Drug Supply Chain Security Act (DSCSA) Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information, released by FDA on 28 November 2014, is meant to address: How information is exchanged between entities within the pharmaceutical supply chain.

DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers was released on 8 December 2014 and explains how wholesalers and third-party logistics providers (3PLs) should report DSCSA information to FDA on an annual basis. Argentina legislation is effective but limited to certain products; however the number of products falling under this legislation is rapidly growing.

In January 2014, ANMAT has published a detailed specification of the central Argentina database (trazabilidat) in Spanish. In December, Brazil published RDC 54/2013, specifying track and trace requirements, accordingly manufacturers must provide serialization and tracking data for three batches of products by 10 December 2015. All pharmaceuticals must be serialized and tracked by 10 December 2016. For a growing market, that’s a critical milestone. On 23 January 2014, the first public hearing discussing implementation was held. Plenty of other countries are preparing for legislation Saudi Arabia by March 2016, Jordan and Ukraine by 2017 including Columbia and Mexico.




The leading companies are demanding solutions that will not only please legislative mandates, but also help them in achieving business benefits beyond compliance. These benefits come from the compact product control that serialization provides. They include:

  • Superior product authentication and integrity, which will protect and enhance the company’s
  • brands and shareholder value
  • Pronounced revenue share by reducing the “gray market” activity that occurs when products are
  • counterfeited and diverted.
  • Finer control over and visibility into the supply chains, leading to accurate shipments.
  • Fast and efficient reverse logistics or recall processes.
  • Serialization also provides huge benefits for clinical trials as they can be conducted, reported and analyzed more efficiently if each of the unit doses being taken in the trial are serialized
  • The healthcare industry can benefit from serialization of medical devices as well
  • Link between the brand owner and the consumer can be used for creative brand loyalty programs
  • (as marketing tool)
  • Companies, in countries with single-payer or other centralized health care systems, reap additional
  • benefits through improved ability to recoup payment from centralized government agencies that reimburse patients drug costs


In order to meet the legislative mandates for serialization, pharmaceutical companies must start planning now. Most of the governments have been extending compliance deadlines, but leading pharmaceutical companies have already started to pivot on implementing a serialization strategy and defining their requirements on trusted partners with production line serialization solutions. The “wait and see” approach by pharmaceutical companies is not the right way as all pharmaceutical companies will be impacted by serialization regulations.In the future, every pack of drug will be expected to have a unique identifier before going to the market and the industry must make amends to adjust to the changes.

In 2011-12, the Australian Pharmaceutical industry clocked in exports of $4.06 billion. In the same year, the industry collected around $6.6 billion from Pharmaceutical Benefits Scheme (PBS) sales. A total of 41,000 people had been employed and the industry spent around $1billion on research and development in 2010-11. According to the Complementary Healthcare Council Annual Report (2011-12), sales of complementary medicines stood at $2 billion a year. The Australian Register of Therapeutic Goods (ARTG) shows a total of 48,000 products on its register, of which there are 21,000 devices and 27,000 drugs, of which only 3,500 are registered prescription-only products.


The drugs manufacturing and marketing is regulated by stringent regulations, based on which companies need to submit an application to the regulatory authority for approval.Australia has been accepting paper and non-eCTD Electronic Submissions (NeeS) format of applications. NeeS, is an electronic application however it is way behind the modern type of application, which is implemented in many other parts of the globe, namely eCTD.  Australia is now moving forward in an effort to go ahead and implement the eCTD format. In the recent past, Australia has inked an agreement with an eCTD software vendor to receive, review and process electronic (eCTD) applications for the entry of prescription medicines and other therapeutic products on to the ARTG. The nation is working closely with the stake holders and plans to implement this modern format for application by the end of 2014.

Regulators at Therapeutic Goods Administration (TGA), will now take a breather owing to this change in the process, however pharmaceutical companies will face a big challenge in moving to this non-familiar format of submissions. Industries will now have to align themselves with various new technical requirements. We might soon witness Australia implementing a more convenient and highly effective format of eCTD.

As an organization, we at Freyr, have always placed the highest value on our business associations and partnerships. It has been our guiding principle to identify newer opportunities and create exceptional engagement excellence for our clients that transform into long-term relationships. As always, it is a great pleasure to announce the New Wins.


  • End-to-end support for submission of a New Drug Application (NDA) to the Saudi Food and Drug Authority (SFDA) including variations
  • Preparation of regulatory submissions in compliance with SFDA guidelines
  • Identification of applicable requirements, including regulatory requirements, market and customer drivers, etc.
  • Enhance project delivery while standardizing regulatory operations
  • Drive improvements in planning and delivery of critical submission project and generate process efficiencies


  • Assessed 40+ Products across diverse Global Brands
  • Submission of fast track Assessment Reports within 6 working days
  • Significant Cost Benefits with Strategic advice on Claim Support for “To-be” marketed products
CLIENT Global Top 5, $70+ Bn, Pharma & Consumer Healthcare Company
FUNCTION Regulatory Affairs
SOLUTION Clinical Cosmetic Safety Assessment
TECHNOLOGICAL ENVIRONMENT Skin Care, Baby Care, Wound Care, Oral Care


The scope of project is to generate the regulatory and market intelligence data for Pharmaceuticals for seven countries in Sub Saharan Africa region identified by the client – Kenya, Ghana, Tanzania, Zambia, Angola, Nigeria and South Africa.


  • The project required performing a Benefit and Risk Assessment Report on the product and Regulatory Filing Strategy
  • The focus was to provide consultation in terms of the clinical safety tests required based on its available data, exposure and intended population


  • Providing rational and scientifically sound clinical safety assessment in a time-bound frame ensuring cost effective solutions
  • Effective communication with the formulators from different countries
  • Helping client to streamline and harmonize Clinical Safety Assessment across all the business regions
  • No clear information about the safety and efficacy of the product


  • Provide highly rational and scientifically sound clinical safety assessment to determine the clinical safety of the Client Products
  • Minimize redundant testing for similar formulations
  • Conducting literature search and compiling the scientific data to enable client to design strategy to elevate their efficacy and safety standards of their products


  • Rationale, sound and scientific assessment enabling client to place the products confidently in market
  • Fast track assessment report delivery timeline within 6 working days
  • Strategic advice on claim support for to-be marketed products
  • Significant cost-reduction by providing technical justification to support the safety of the product
  • Freyr has assessed over 40 products across diverse global brands


  • Master Dossier Creation for Future Markets
  • Dossier Harmonization for 12 Countries
  • 80% Time Effort Reduction
  • 40% Savings on Cost of Compliance
CLIENT Global Top 5, $70+ Bn, Pharma & Consumer Healthcare Company
GEOGRAPHY South Africa and Sub -Sahara Countries
FUNCTION Regulatory Affairs
SOLUTION SSA Quality Variation


  • The client needed support in filing 24 CMC variations for an established medicinal product in SA and SSA countries
  • The product is used to treat haemorrhoids and other anorectal conditions.
  • The scope included updating the registered information with current regulatory requirements and harmonize the dossier for 12 African countries for multiple dosage forms within short span of a few months


  • The client faced strict timelines coupled with coordination across local markets
  • Distributed country specific source documents
  • Coordination with the proposed drug product manufacturing sites
  • Country specific publishing requirements


  • Compliance with product manufacturing change communication to health authorities in a timely fashion
  • Harmonized master dossier approach and reduced the time effort by 80%
  • 40% Savings on Cost of Compliance
  • Master Dossier Creation for Future Markets


  • A unique approach to create a long term streamlined solution in addressing future change controls by harmonizing the country specific dossiers into a master dossier
  • Gap Analysis
  • Master Dossier Creation
  • Country Variation
  • Program Management Approach